Items Tagged ‘Stages II-III Breast Cancer’

July 27th, 2016

Neratinib Improves Cancer-Free Survival in Early Breast Cancer

By

The targeted agent neratinib (PB272), which is still in clinical trials, demonstrated an improvement in cancer-free survival when used after Herceptin® (trastuzumab) in early-stage, HER2-positive breast cancer. Approximately 20-30% of breast cancer is referred to as human epidermal growth factor receptor-2 (HER2)-positive.  This means that the breast cancer cells have too many HER2 proteins on […]

View full entry

Tags: Breast Cancer, early breast cancer, exteNET, HER2-positive, herceptin, neratinib, News, Stage I Node Negative Breast Cancer, Stages II-III Breast Cancer, trastuzumab. her2


April 28th, 2016

Some Premenopausal Women Benefit from Exemestane Compared to Tamoxifen

By

Among premenopausal women with hormone-positive, early breast cancer who are considered to have a high risk of a cancer recurrence, the use of Aromasin® (exemestane) versus tamoxifen improves cancer-free survival at 5 years. These results were recently published in the Journal of Clinical Oncology. The majority of breast cancers, referred to as hormone-positive breast cancers, […]

View full entry

Tags: aromasin, Breast Cancer, exemestane, HER2-negative, hormone-positive, News, premenopausal, Stage I Node Negative Breast Cancer, Stages II-III Breast Cancer, tamoxifen


March 28th, 2016

Dose-Dense Chemotherapy for Premenopausal Breast Cancer Improves Survival

By

Premenopausal women who have been diagnosed with breast cancer have improved survival if their chemotherapy doses are delivered every two weeks, compared to every three weeks. These results were recently presented at the 2016 European Breast Cancer Conference (EBCC-10) in the Netherlands. Chemotherapy following surgery is a standard treatment option for premenopausal women diagnosed with […]

View full entry

Tags: Breast Cancer, clinical trials, dose-dense, Metastatic Breast Cancer, News, premenopausal, research, Stage I Node Negative Breast Cancer, Stages II-III Breast Cancer


January 25th, 2016

ASCO Publishes Breast Cancer Survivorship Guidelines

By

The American Society of Clinical Oncology (ASCO), in collaboration with the American Cancer Society (ACS), have released updated guidelines regarding follow-up care for breast cancer survivors. The updated guidelines were recently published in the Journal of Clinical Oncology. There is an estimated 3.1 million breast cancer survivors alive today in the United States. At present, […]

View full entry

Tags: ACS, American cancer society, American Society of Clinical Oncology, Breast Cancer, Carcinoma In Situ Breast cancer, follow-up, guidelines, Inflammatory Breast Cancer, Metastatic Breast Cancer, News, Recurrent Breast Cancer, Screening/Prevention Breast Cancer


January 3rd, 2016

Conjugate Drug Extends Survival in Patients with Advanced HER2-Positive Breast Cancer

By

Patients with metastatic, HER2-positive breast cancer received a combination antibody/chemotherapy drug in a phase 3 clinical trial survived longer, on average, than patients receiving other treatments. Researchers from Dana-Farber Cancer Institute reported the findings at the 2015 San Antonio Breast Cancer Symposium. The TH3RESA trial, which enrolled more than 600 participants in the U.S. and […]

View full entry

Tags: Breast Cancer, HER2-positive, metastatic, Metastatic Breast Cancer, News, Stages II-III Breast Cancer, T-DMI, TH3RESA trial, trastuzumab emtansine


September 16th, 2015

A Vegan or Vegetarian Diet May Help Improve Treatment of Triple-Negative Breast Cancer

By

Early research suggests that a vegan or vegetarian diet low in the amino acid methionine may help improve treatment of triple-negative breast cancers. These findings were reported in the journal Clinical Cancer Research. The majority of breast cancers are hormone receptor-positive, meaning that the cancer cells are stimulated to grow from exposure to the female […]

View full entry

Tags: Breast Cancer, diet, HER2-negative, News, Stage I Node Negative Breast Cancer, Stages II-III Breast Cancer, TRAIL-R2, treatment, triple negative, vegan, vegetarian


September 8th, 2015

Biomarker May Help Improve Treatment of Triple-Negative Breast Cancer

By

Researchers have found a biomarker that appears active in the growth and spread of triple-negative breast cancer. Known as interleukin-13 receptor alpha 2 (IL13Ralpha2), the biomarker may help doctors identify patients at high risk of disease spread and potentially provide a target for treatment. These findings were reported in Breast Cancer Research. The majority of […]

View full entry

Tags: biomarker, Breast Cancer, Carcinoma In Situ Breast cancer, HER2-negative, IL13Ralpha2, News, Stage I Node Negative Breast Cancer, Stages II-III Breast Cancer, Triple Negative Breast Cancer


September 1st, 2015

Women with Early Breast Cancer Have Fewer Side Effects with Shorter Courses of Radiation

By

Women with early breast cancer have fewer side effects when they’re treated with shorter courses of radiation at higher doses than with conventional radiation to the whole breast. These findings were reported in JAMA Oncology.[1] Treatment with shorter course of radiation at higher doses is known as hypofractionated radiation therapy. This approach allows for less […]

View full entry

Tags: Breast Cancer, Carcinoma In Situ Breast cancer, conventional radiation, DCIS, hypofractionated radiation therapy, News, radiation, Stage I, Stage I Node Negative Breast Cancer, Stage II, Stages II-III Breast Cancer


August 4th, 2015

Role of Tumor Size and Estrogen-Receptor Status in Decline in Breast Cancer Deaths

By

In light of a general decline in breast cancer death since the late 1980s, research has now turned to how type and stage of disease affect survival among different women. These findings, which considered tumor size and estrogen-receptor (ER) status, were reported in the Journal of Clinical Oncology. The death rate from breast cancer overall has […]

View full entry

Tags: Breast Cancer, Metastatic Breast Cancer, News, Recurrent Breast Cancer, Stages II-III Breast Cancer


April 30th, 2015

Dose-Dense Chemotherapy with Ellence®, Cytoxan®, and Taxol® May Improve Survival in Node-Positive Breast Cancer

By

Patients with early-stage node-positive breast cancer who receive dose-dense adjuvant chemotherapy with Ellence® (epirubicin), Cytoxan® (cyclophosphamide), and Taxol® (paclitaxel) may have improved disease-free survival. These findings were released online by the journal The Lancet. Node-positive breast cancer means that cancer cells from the breast have been found in the lymph nodes under the arm. Although […]

View full entry

Tags: Breast Cancer, cyclophosphamide, Cytoxan, early-stage, Ellence, epirubicin, fluorouracil, News, node-positive, paclitaxel, Stages II-III Breast Cancer, Taxol


March 24th, 2015

Herceptin Superior to Tykerb for Treatment of HER2-positive Breast Cancer

By

In patients with human epidermal growth factor receptor (HER2)–positive advanced breast cancer, the combination of Herceptin® (trastuzumab) plus a taxane resulted in delayed time to cancer progression and was associated with fewer side effects than Tykerb® (lapatinib) plus a taxane, according to final clinical trial results reported in the Journal of Clinical Oncology. The HER2 […]

View full entry

Tags: Breast Cancer, HER2, herceptin, lapatinib, Metastatic Breast Cancer, News, Stages II-III Breast Cancer, trastuzumab, Tykerb


January 27th, 2015

Breast Cancer Research: Have We Made Progress?

By

Published results from research studies in breast cancer in the last year represent several practice changing milestones. CancerConnect News coverage of advances in the management of breast cancer included the following key developments: 2014: Have we Made Progress? Recent Study Finds That African American Women Less Likely To Receive Standard Breast Cancer Treatment Breast Cancer […]

View full entry

Tags: Breast Cancer, breast cancer research, Carcinoma In Situ Breast cancer, Inflammatory Breast Cancer, Metastatic Breast Cancer, News, Recurrent Breast Cancer, Screening/Prevention Breast Cancer, Stage I Node Negative Breast Cancer, Stages II-III Breast Cancer, Supportive Care Breast Cancer


December 19th, 2014

Study Confirms Role of Ovarian Suppression and Aromasin for Younger Women With Hormone-sensitive Breast Cancer

By

Ovarian suppression combined with the anti-estrogen drug Aromasin® (exemestane) appears to greatly reduce the risk of breast cancer recurrence in younger women according to the results of the Suppression of Ovarian Function Trial (SOFT) presented at the 2014 San Antonio Breast Cancer Symposium in Texas.[1] These results were also published online simultaneously in The New […]

View full entry

Tags: aromasin, Breast Cancer, News, ovarian suppression, Stage I Node Negative Breast Cancer, Stages II-III Breast Cancer, tamoxifen


December 18th, 2014

Breast Cancer Patients Are Now Living Longer without Relapse

By

Survival without relapse for patients with early-stage breast cancer has improved significantly over the past 30 years, particularly among women with HER2-positive disease. These findings were recently published in the Journal of Clinical Oncology. Cancer is considered relapsed when disease returns after it has been in remission following treatment, meaning that signs and symptoms have disappeared. Preventing relapse—or […]

View full entry

Tags: Breast Cancer, cancer, HER2, News, recurrence, Recurrent Breast Cancer, Stage I Node Negative Breast Cancer, Stages II-III Breast Cancer


December 12th, 2014

Exercise Significantly Reduces Joint Pain Caused by Hormone Therapy Taken by Patients With Breast Cancer

By

According to a study published this week in the Journal of Clinical Oncology regular exercise helps relieve arthritic joint pain associated with aromatase inhibitor (AI) drugs used to treat breast cancer.1 Aromatase inhibitors are widely used in the treatment of estrogen receptor positive early and late stage breast cancer, and can also reduce the likelihood […]

View full entry

Tags: AI, arthritic, Breast Cancer, exercise, News, Stage I Node Negative Breast Cancer, Stages II-III Breast Cancer